N/A
N=125
Evaluate St Jude Medical Prodigy Neuromodulation for FBSS or Chronic Pain of the Trunk and/or Limbs
Chronic Pain
Bottom Line
View on ClinicalTrials.gov: NCT02143791 ↗Enrolled (actual)
125
Serious AEs
31.0%
Results posted
Jul 2024
Primary outcome: Primary: Percentage Change From Baseline in Overall VAS at 3 Months — -51.3 Percentage change
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Burst and Tonic stimulation (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Abbott Medical Devices
- Primary completion
- Jan 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change From Baseline in Overall VAS at 3 Months |
-51.3 | — |
| SECONDARY Pain Relief |
55.5 | — |
| SECONDARY Pain Relief |
55.5 | — |
| SECONDARY Pain Relief |
55.5 | — |
| SECONDARY Change in Pain Catastrophizing Scale |
-13 | — |
| SECONDARY Number of Participants With Analgesic Reduction |
3 | — |
| SECONDARY Change in Quality of Life |
46; 62 | — |
| SECONDARY Rate of Serious Adverse Events and/or Procedure/Device-related Adverse Events |
57; 24 | — |
| SECONDARY Paresthesia Mapping at 3 Months Compared to the Empower Study |
18.2 | — |
Summary
The purpose of this study is to confirm long term efficacy and safety of the ProdigyTM neuromodulation system in the management of failed back surgery syndrome or chronic intractable pain of the trunk and/or limbs.
Eligibility Criteria
Inclusion Criteria
- Patient with chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome or intractable low back and/or leg pain
- Patient diagnosed with radiculopathy
- Patient diagnosed with neuropathic pain
- Patient is considered by the investigator as a candidate for implantation of a SCS system
- Patient is ≥ 18 years of age
- Patient must be willing and able to comply with study requirements
- Patient must indicate his/her understanding of the study and willingness to participate by signing an appropriate Informed Consent Form
Exclusion Criteria
- Patient is diagnosed with ischemic pain
- Patient is diagnosed with arachnoiditis
- Patient is diagnosed with complex regional pain syndrome (CRPS I and II)
- Patient is diagnosed with peripheral vascular disease (PVD)
- Patient is diagnosed with diabetic neuropathic pain
- Patient is diagnosed with chronic migraine
- Patient is immune-compromised
- Patient has history of cancer requiring active treatment in the last 6 months
- Patient has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the last 6 months
- Patients with a SCS system or implantable infusion pump implanted previously
- Patient has a life expectancy of less than one year
- Patient is pregnant or is planning to become pregnant during the duration of the investigation
- Patient is unable to comply with the follow up schedule
- Patient needing legally authorized representative
- Patient unable to read and write
- Patient is currently participating in another clinical investigation with an active treatment arm.
Data sourced from ClinicalTrials.gov (NCT02143791). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.